Abstract
Our study analyzes the mobilization of hematopoietic stem cells after two chemotherapeutic regimens in non-Hodgkin's lymphoma (NHL) patients. The study included 72 patients with NHL (42 follicular and 30 large cells). The mean age was 37 years (range 17–60). Sixty-four patients (88.9%) had stage III–IV disease. Forty-eight patients (66.7%) had bone marrow involvement. Systemic B symptoms were present in 42 patients (58.3%). Mobilization chemotherapy regimens were randomly assigned as DHAP in 38 patients (52.7%) or cyclophosphamide (CPM) (5 g/m2) in 34 (47.2%) and the results of 132 procedures were analyzed. At the time of PBSC mobilization, 46 patients (63.9%) were considered to be responsive (complete remission, partial remission or sensitive relapse) and 26 (36.1%) not responsive (refractory relapse or refractory to therapy). Pre-apheresis CD34+ blood cell count and number of previous chemotherapy treatments were used to predict the total number of CD34+ cells in the apheresis product. The mobilizing regimens (CPM or DHAP) were similar in achieving the threshold CD34+ cell yield, for optimal engraftment. Since DHAP was very effective as salvage treatment, we suggest using DHAP as a mobilizing regimen in patients with active residual lymphoma at the time of stem cell collection.
Bone Marrow Transplantation (2002) 29, 285–290. doi:10.1038/sj.bmt.1703364
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Haas R, Moos M, Mohle R et al. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma Bone Marrow Transplant 1996 17: 149 155
Pettengell R, Radford JA, Morgenstern GR et al. Survival benefit from high-dose therapy with autologous blood progenitor cell transplantation in poor-prognosis non-Hodgkin's lymphoma J Clin Oncol 1996 14: 586 592
Tarella C, Castellino C, Cherasco C et al. Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome Br J Haematol 1997 99: 41 46
Gratwohl A, Hermans J, Baldomero H . Haematopoietic precursors cell transplants in Europe: activity in 1994. Report from the European Group for Blood and Marrow transplantation Bone Marrow Transplant 1996 17: 137 148
Webb IJ, Eickhoff CE, Elias AD et al. Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collections Transfusion 1996 36: 160 167
Millar BC, Millar JL, Shepherd V et al. The importance of CD34+/CD33− cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue Bone Marrow Transplant 1998 22: 469 475
Turner ML . Regulation of hematopoietic progenitor cell migration, mobilization and homing Stem Cells 1994 12: 227 229
Kobayashi M, Imamura M, Uede T et al. Expression of adhesion molecules on human hematopoietic progenitor cells at different maturational stages Stem Cells 1994 12: 316 321
Goldscmidt H, Hegenbart U, Haas R et al. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4–7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma Bone Marrow Transplant 1996 17: 691 697
Watts MJ, Sullivan AM, Jamieson E et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma J Clin Oncol 1997 15: 535 546
Lozano ML, Ortuno F, de Arriba F et al. Effect of rhG-CSF on the mobilization of CD38 and HLA-DR subfractions of CD34+ peripheral blood progenitor cells Ann Hematol 1995 71: 105 110
Haas R, Murea S . The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells Cytokines Mol Ther 1995 1: 249 270
Olivieri A, Offidani M, Ciniero L et al. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma Bone Marrow Transplant 1995 16: 85 93
McQuaker IG, Haynes AP, Stainer C et al. Stem cell mobilization in resistant or relapsed lymphoma: superior yield ofprogenitor cells following a salvage regimen comprisingifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide Br J Haematol 1997 98: 228 233
Mayer J, Koristek Z, Vasova I et al. Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma Bone Marrow Transplant 1999 23: 413 419
Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) Blood 1988 71: 117 122
Press OW, Livingston R, Mortimer J et al. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation J Clin Oncol 1991 9: 423 431
Vela-Ojeda J, Tripp-Villanueva F et al. Propective randomized clinical trial comparing ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization Bone Marrow Transplant 2000 25: 1141 1146
Watts MJ, Leverett D, Sullivan AM et al. A comparison of ESHAP + G-CSF vs cyclophosphamide 1.5 g/m2 for PBSC mobilization in pre-treated lymphoma patients: a matched pair analysis Blood 1996 88: (Suppl. 1) Abstr. 1571
Watts MJ, Sullivan AM, Leverett D . Evaluation of the ESHAP regimen followed by G-CSF for PBSC mobilization: a matched pairs analysis compared to low dose cyclophosphamide 1.5 g/m2 plus G-CSF Br J Haematol 1996 93: (Suppl. 1) Abstr. 67
Sutherland Dr, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry J Hematother 1996 5: 213 216
Ghio R . Le tecniche di coltura in vitro dei progenitori emopoietici umani Colture Cellulari; a cura di Sitia R Scuola Superiore di Oncologia e Scienze Biomediche 1989 S1: p 145
Ketterer N, Salles G, Moullet I et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies Br J Haematol 1998 103: 235 242
Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma Blood 1994 83: 3787 3794
Perry AR, Watts MJ, Peniket AJ et al. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy Bone Marrow Transplant 1998 21: 1201 1205
Moskowitz CH, Glassman JR, Wuest D et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma Clin Cancer Res 1998 4: 311 316
Carlo-Stella C, Tabilio A, Regazzi E et al. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors Bone Marrow Transplant 1997 20: 465 471
Shimizu E, Yamamoto A, Takahashi Y et al. Effect of alternating combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide for small cell lung cancer on hematopoietic progenitors in the peripheral blood Br J Cancer 1993 67: 798 800
Kronenwett R, Martin S, Haas R . The role of cytokine and mobilization of peripheral blood stem cells Stem Cell 2000 18: 320 330
McNiece IK, Briddell RA, Hartley CA, Andrews RG . The role of stem cell factor in mobilization of peripheral blood progenitor cells: synergy with G-CSF Stem Cells 1993 11: (Suppl. 3) 83 88
Schwella N, Siegert W, Beyer J et al. Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution Ann Hematol 1995 71: 227 234
Fontao-Wendel R, Lazar A, Melges S et al. The absolute number of circulating CD34+ cells as the best predictor of peripheral hematopoietic stem cell yield J Hematother 1999 8: 255 262
Philip T, Chauvin F, Armitage J et al. Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation Blood 1991 77: 1587 1592
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pavone, V., Gaudio, F., Guarini, A. et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 29, 285–290 (2002). https://doi.org/10.1038/sj.bmt.1703364
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703364
Keywords
This article is cited by
-
Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials
Stem Cell Research & Therapy (2022)
-
Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization
BMC Cancer (2020)
-
Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma
Bone Marrow Transplantation (2016)
-
Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group
Annals of Hematology (2016)
-
Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study
Annals of Hematology (2016)